← Back to Clinical Trials
Recruiting NCT06462274

Biomarkers and Imaging Markers for ICH

◆ AI Clinical Summary
Plain-language summary for patients

Trial Parameters

Condition Intracerebral Hemorrhage
Sponsor Southwest Hospital, China
Study Type OBSERVATIONAL
Phase N/A
Enrollment 200
Sex ALL
Min Age 18 Years
Max Age 80 Years
Start Date 2014-01-01
Completion 2026-06-01
Interventions
body sample collection and imaging scan

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

Brief Summary

Intracerebral hemorrhage (ICH) is a subtype of stroke associated with high mortality and disability. Basic and clinical research has contributed to our understanding of the complex pathophysiology in ICH. However, questions regarding acute diagnosis, therapeutic decisions, and prognostication of ICH remain unanswered. Molecular biomarkers and imaging markers have revolutionalized diagnosis and treatment of many diseases, such as troponin use in myocardial infarction and magnetic resonance imaging (MRI) scan in ischemic stroke. Therefore, the investigators aim to discovery the potential biomarkers by screening samples of blood, cerebral spinal fluid, urine, saliva, and even tissues (if available) from ICH patients, and imaging markers via serial multimodality imaging scans such as computed tomography(CT), magnetic resonance imaging (MRI), magnetic resonance spectroscopy (MRS), positron emission tomography (PET), etc. These molecular and imaging markers would assist in contributing additional information to current tools for onset warning, diagnosis, therapy monitoring, risk stratification, intervention and prognosis for ICH patients.

Eligibility Criteria

Inclusion Criteria: 1. Individuals aged 18-80 years 2. Hematoma size is more than 5 ml 3. Evidence of a spontaneous ICH on CT scan 4. Patient within 72 hours of ictus 5. Glasgow Coma Scale (GCS) Score of 5-15. 6. The history of hypertension Exclusion Criteria: 1. Individuals with age \< 18 years or \> 80 years 2. Clear evidence that the hemorrhage is due to an aneurysm, arteriovenous malformation or other cerebrovascular diseases. 3. ICH secondary to tumor or trauma.. 4. If the haematological effects of any previous anticoagulants are not completely reversed. 5. Patients with heart insufficiency, lungs insufficiency, renal insufficiency, hepatic insufficiency, autoimmune diseases and other organ diseases with severe dysfunction.

Related Trials

}
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology